Evidence map›Paper›PMID 25483648›Full record

ReviewHuman vaccines & immunotherapeutics2014

Live attenuated pre-erythrocytic malaria vaccines.

Gladys J Keitany, Marissa Vignali, Ruobing Wang

Open access · bronzeAbstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Advances in Vaccines.Advances in biochemical engineering/biotechnology · 2020
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Gladys J Keitanya Seattle Biomedical Research Institute ; Seattle , WA USA.
Marissa Vignali
Ruobing Wang
Seattle University · USCenter for Infectious Disease Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although recent control measures have significantly reduced malaria cases and deaths in many endemic areas, an effective vaccine will be essential to eradicate this parasitic disease. Malaria vaccine strategies developed to date focus on different phases of the parasite's complex life cycle in the human host and mosquito vector, and include both subunit-based and whole-parasite vaccines. This review focuses on the 3 live-attenuated malaria vaccination strategies that have been tested in humans to date, and discusses their progress, challenges and the immune correlates of protection that have been identified.

Indexed as

Antibodies, ProtozoanHumansMalaria, FalciparumMalaria VaccinesMalaria, VivaxPlasmodium falciparumPlasmodium vivaxProtozoan ProteinsSporozoitesVaccinationVaccines, AttenuatedAntibodies, ProtozoanMalaria VaccinesProtozoan ProteinsVaccines, AttenuatedattenuationCPS, Chemoprophylaxis and Sporozoite immunizationCQ, chloroquineCSP, circumsporozoite proteinGAP, Genetically Attenuated Parasitei.d., intradermalITV, Immunization-Treatment-Vaccinationi.v., intravenousMalariaP. falciparumPfSPZ, P. falciparum sporozoite vaccinepre-erythrocyticRAS, Radiation Attenuated Sporozoitess.c., subcutaneouswhole-parasite vaccines

Identifiers

PMID25483648
PMCPMC5443077
OpenAlexW2010856942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.